Today, FDA approved a treatment for adult patients with recurrent or metastatic head and neck squamous cell cancer whose disease has progressed on or after platinum-based chemotherapy and immunotherapy.
This is an aggressive, life-threatening disease for which there is a high unmet need for effective therapies. fda.gov/news-events/press-an…
3
FDA approves amivantamab (EGFR/MET bispecific) for R/M HNSCC based on the results of the OrigAMI-4 trial
Today, FDA approved a treatment for adult patients with recurrent or metastatic head and neck squamous cell cancer whose disease has progressed on or after platinum-based chemotherapy and immunotherapy.
This is an aggressive, life-threatening disease for which there is a high unmet need for effective therapies. fda.gov/news-events/press-an…
1
141